UBS Maintains Buy on Tenet Healthcare, Raises Price Target to $104
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Andrew Mok maintains a Buy rating on Tenet Healthcare (NYSE:THC) and raises the price target from $95 to $104.
August 04, 2023 | 9:43 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Andrew Mok maintains a Buy rating on Tenet Healthcare and raises the price target from $95 to $104. This could potentially lead to an increase in the stock's price.
The raised price target by UBS indicates a positive outlook for Tenet Healthcare. This could potentially attract more investors, leading to an increase in demand for the stock and subsequently, a rise in its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100